Cancer treatment and research Journal Impact Factor & Information

Publisher: Kluwer

Current impact factor: 0.00

Impact Factor Rankings

Additional details

5-year impact 0.00
Cited half-life 0.00
Immediacy index 0.00
Eigenfactor 0.00
Article influence 0.00
Other titles CTAR
ISSN 0927-3042
OCLC 311541220
Material type Series
Document type Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Authors own final version can be archived
    • Publisher's protected PDF can be used for a fee
    • Published source must be acknowledged
    • Must link to publisher version
    • Articles in some journals can be made Open Access on payment of additional charge
    • 'Kluwer' is an imprint of 'Springer Verlag (Germany)'
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Disease heterogeneity within and between patients necessitates a patient-focused approach to cancer treatment. This exigency forms the basis for the medical practice termed personalized medicine. An emerging, important component of personalized medicine is theranostics. Theranostics describes the co-delivery of therapeutic and imaging agents in a single formulation. Co-delivery enables noninvasive, real-time visualization of drug fate, including drug pharmacokinetic and biodistribution profiles and intratumoral accumulation. These technological advances assist drug development and ultimately may translate to improved treatment planning at the bedside. Nanocarriers are advantageous for theranostics as their size and versatility enables integration of multiple functional components in a single platform. This chapter focuses on recent developments in advanced lipid theranostic nanomedicine from the perspective of the "all-in-one" or the "one-for-all" approach. The design paradigm of "all-in-one" is the most common approach for assembling theranostic lipid nanoparticles, where the advantages of theranostics are achieved by combining multiple components that each possesses a specific singular function for therapeutic activity or imaging contrast. We will review lipoprotein nanoparticles and liposomes as representatives of the "all-in-one" approach. Complementary to the "all-in-one" approach is the emerging paradigm of the "one-for-all" approach where nanoparticle components are intrinsically multifunctional. We will discuss the "one-for-all" approach using porphysomes as a representative. We will further discuss how the concept of "one-for-all" might overcome the regulatory hurdles facing theranostic lipid nanomedicine.
    Cancer treatment and research 04/2015; 166:103-27. DOI:10.1007/978-3-319-16555-4_5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intracellular delivery of functional proteins using nanoparticles can be a game-changing approach for cancer therapy. However, cytosolic release of functional protein is still a major challenge. In addition, formation of protein corona on the surface of the nanoparticles can also alter the behavior of the nanoparticles. Here, we will review recent strategies for protein delivery into the cell. Finally we will discuss the issue of protein corona formation in light of nanoparticle-protein interactions.
    Cancer treatment and research 04/2015; 166:245-73. DOI:10.1007/978-3-319-16555-4_11
  • [Show abstract] [Hide abstract]
    ABSTRACT: To be legally sold in the United States, all drugs must go through the FDA approval process. This chapter introduces the FDA approval process and describes the clinical trials required for a drug to gain approval. We then look at the different cancer nanotherapeutics and in vivo diagnostics that are currently in clinical trials or have already received approval. These nanotechnologies are catagorized and described based on the delivery vehicle: liposomes, polymer micelles, albumin-bound chemotherapeutics, polymer-bound chemotherapeutics, and inorganic particles.
    Cancer treatment and research 04/2015; 166:293-322. DOI:10.1007/978-3-319-16555-4_13
  • Dean Ho ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The advent of cancer nanomedicine has forged new pathways for the enhanced imaging and treatment of a broad range of cancers using new classes of materials. Among the many platforms being developed for drug delivery and imaging, nanodiamonds (NDs) possess several important attributes that may be beneficial toward improving the efficacy and safety of cancer nanomedicine applications. These include the uniquely faceted surfaces of the ND particles that result in electrostatic properties that mediate enhanced interactions with water and loaded therapeutic compounds, scalable processing and synthesis parameters, versatility as platform carriers, and a spectrum of other characteristics. In addition, comprehensive in vitro and in vivo studies have demonstrated that NDs are well tolerated. This chapter will examine several recent studies that have harnessed the ND agent as a foundation for both systemic and localized drug delivery, as well as the marked improvements in magnetic resonance imaging efficiency that has been observed following ND-contrast agent conjugation. In addition, insight into the important steps toward bringing the ND translational pathway to the clinic will be discussed.
    Cancer treatment and research 04/2015; 166:85-102. DOI:10.1007/978-3-319-16555-4_4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients whose cancer is detected early are much more likely to have a positive prognosis and outcome. Nanoflares hold promise as a practical diagnostic platform for the early detection of cancer markers in living cells. These probes are based on spherical nucleic acid (SNAs) and are typically composed of gold nanoparticle cores and densely packed and highly oriented oligonucleotide shells; these sequences are complementary to specific mRNA targets and are hybridized to fluorophore-labeled reporter strands. Nanoflares take advantage of the highly efficient fluorescence quenching properties of gold, the rapid cellular uptake of SNAs that occurs without the use of transfection agents, and the enzymatic stability of such constructs to report a highly sensitive and specific signal in the presence of intracellular target mRNA. In this chapter, we will focus on the synthesis, characterization, and diagnostic applications of nanoflares as they relate to cancer markers.
    Cancer treatment and research 04/2015; 166:1-22. DOI:10.1007/978-3-319-16555-4_1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hybrid nanoparticles, composed of both inorganic and organic components, have been exploited as promising platforms for cancer imaging and therapy. This class of nanoparticles can not only retain the beneficial features of both inorganic and organic materials, but also allow systematic fine-tuning of their properties through the judicious combination of functional components. This chapter summarizes recent advances in the design and synthesis of hybrid nanomaterials, with particular emphasis on two main categories of hybrid nanoparticles: Nanoscale metal-organic frameworks (also known as nanoscale coordination polymers) and polysilsesquioxane nanoparticles. Preliminary applications of these hybrid nanoparticles in cancer imaging and therapy are described.
    Cancer treatment and research 04/2015; 166:173-92. DOI:10.1007/978-3-319-16555-4_8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Spherical nucleic acids (SNAs) represent an emerging class of nanoparticle-based therapeutics. SNAs consist of densely functionalized and highly oriented oligonucleotides on the surface of a nanoparticle which can either be inorganic (such as gold or platinum) or hollow (such as liposomal or silica-based). The spherical architecture of the oligonucleotide shell confers unique advantages over traditional nucleic acid delivery methods, including entry into nearly all cells independent of transfection agents and resistance to nuclease degradation. Furthermore, SNAs can penetrate biological barriers, including the blood-brain and blood-tumor barriers as well as the epidermis, and have demonstrated efficacy in several murine disease models in the absence of significant adverse side effects. In this chapter, we will focus on the applications of SNAs in cancer therapy as well as discuss multimodal SNAs for drug delivery and imaging.
    Cancer treatment and research 04/2015; 166:23-50. DOI:10.1007/978-3-319-16555-4_2
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are currently no nanoparticle formulations that optimally target diseased cells in the body. A small percentage of nanoparticles reach these cells and most accumulate in cells of the mononuclear phagocytic system. This chapter explores the interactions between nanoparticles and cells that may explain the causes for off-target accumulation of nanoparticles. A greater understanding of the nanoparticle-cellular interactions will lead to improvements in particle design for improved therapeutic outcome.
    Cancer treatment and research 04/2015; 166:227-44. DOI:10.1007/978-3-319-16555-4_10
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent developments in nanotechnology have brought new approaches to cancer diagnosis and therapy. While enhanced permeability and retention effect (EPR) promotes nanoparticle (NP) extravasation, the abnormal tumor vasculature, high interstitial pressure and dense stroma structure limit homogeneous intratumoral distribution of NP and compromise their imaging and therapeutic effect. Moreover, heterogeneous distribution of NP in nontumor-stroma cells damages the nontumor cells, and interferes with tumor-stroma crosstalk. This can lead to inhibition of tumor progression, but can also paradoxically induce acquired resistance and facilitate tumor cell proliferation and metastasis. Overall, the tumor microenvironment plays a crucial, yet controversial role in regulating NP distribution and their biological effects. In this review, we summarize recent studies on the stroma barriers for NP extravasation, and discuss the consequential effects of NP distribution in stroma cells. We also highlight design considerations to improve NP delivery and propose potential combinatory strategies to overcome acquired resistance induced by damaged stroma cells.
    Cancer treatment and research 04/2015; 166:193-226. DOI:10.1007/978-3-319-16555-4_9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nanoparticle properties such as size, shape, deformability, and surface chemistry all play a role in nanomedicine drug delivery in cancer. While many studies address the behavior of particle systems in a biological setting, revealing how these properties work together presents unique challenges on the nanoscale. "Calibration-quality" control over such properties is needed to draw adequate conclusions that are independent of parameter variability. Furthermore, active targeting and drug loading strategies introduce even greater complexities via their potential to alter particle pharmacokinetics. Ultimately, the investigation and optimization of particle properties should be carried out in the appropriate preclinical tumor model. In doing so, translational efficacy improves as clinical tumor properties increase. Looking forward, the field of nanomedicine will continue to have significant clinical impacts as the capabilities of nanoparticulate drug delivery are further enhanced.
    Cancer treatment and research 04/2015; 166:275-91. DOI:10.1007/978-3-319-16555-4_12
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of colorectal cancer is becoming more uniform, with wider acceptance of standardized guidelines. However, areas of controversy exist where the appropriate treatment is not clear, including: should a segmental colectomy or a more extensive resection be performed in hereditary nonpolyposis colorectal cancer? should an asymptomatic primary cancer be resected in the presence of unresectable metastatic disease? what is the role of extended lymph node resection in colon and rectal cancer? are there clinically significant benefits for a robotic approach to colorectal resection versus a laparoscopic approach? This chapter will examine these issues and discuss how they may be resolved.
    Cancer treatment and research 02/2015; 164:143-163. DOI:10.1007/978-3-319-12553-4_9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Controversies abound in urologic cancers. While some work in comparative effectiveness research has been performed, most controversies remain unresolved. In this chapter, we examine the three most common urologic malignancies: Prostate cancer, kidney cancer, and bladder cancer. We will review progress made in comparative effectiveness research for each cancer and outline important topics where future research is needed.
    Cancer treatment and research 02/2015; 164:221-235. DOI:10.1007/978-3-319-12553-4_12
  • [Show abstract] [Hide abstract]
    ABSTRACT: The field of gynecologic oncology is faced with a number of challenges including how to incorporate new drugs and procedures into practice, how to balance therapeutic efficacy and toxicity of treatment, how to individualize therapy to particular patients or groups of patients, and how to contain the rapidly rising costs associated with oncologic care. In this chapter we examine three common and highly debated clinical scenarios in gynecologic oncology: the initial management of ovarian cancer, the role of lymphadenectomy in the treatment of endometrial cancer, and the choice of adjuvant therapy for ovarian cancer.
    Cancer treatment and research 02/2015; 164:237-259. DOI:10.1007/978-3-319-12553-4_13
  • [Show abstract] [Hide abstract]
    ABSTRACT: Controversies in treatment of thyroid cancer remain despite numerous published studies. Robust comparative effectiveness studies examining: (1) the role of prophylactic central compartment neck dissection (pCCND) in patients with papillary thyroid cancer (PTC); (2) the use of post-operative radioactive iodine (RAI) ablation therapy following total thyroidectomy; (3) use of low versus high doses of I-131 in RAI therapy; (4) thyroid hormone withdrawal (THW) versus recombinant thyroid stimulating hormone (rhTSH) prior to RAI; and (5) the role of routine measurement of serum calcitonin levels are needed to help strengthen existing treatment recommendations. Reasons for the controversies and suggestions for quality comparative effectiveness studies are discussed.
    Cancer treatment and research 02/2015; 164:67-87. DOI:10.1007/978-3-319-12553-4_5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is the most commonly diagnosed cancer among women. To date, the use of efficacy randomized controlled trials (RCTs) in breast cancer have resulted in dramatic improvements in oncologic outcomes for this disease. However, not every question pertinent to breast cancer is amenable to such efficacy trials. This chapter will discuss some of the unique aspects of breast cancer that make efficacy RCTs challenging and/or impractical, how comparative effectiveness research can be used to address these issues, and identify several key questions which would benefit from ongoing comparative effectiveness research.
    Cancer treatment and research 02/2015; 164:15-30. DOI:10.1007/978-3-319-12553-4_2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer accounts for more cancer deaths than breast, prostate, colorectal and pancreatic cancer combined. With an aging population, greater intensity of cancer care, and the need for care of the growing number of cancer survivors, comparative effectiveness research opportunities will continue to emerge for this disease. In this chapter, we focus on CER opportunities in lung cancer surgery from the vantage point of those factors directly influenced by the surgeon, patient and the healthcare system.
    Cancer treatment and research 02/2015; 164:101-119. DOI:10.1007/978-3-319-12553-4_7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite advances in cancer care, pancreatic adenocarcinoma remains one of the most lethal tumors. Most patients with pancreatic cancer are diagnosed with late stage disease, and approximately 6 % of patients are alive 5 years after diagnosis. Of the 10-20 % of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25 % (Lim et al. in Annals of surgery 237(1):74-85, 2003 [1]; Trede et al. in Annals of surgery 211(4):447-458, 1990 [2]; Crist et al. in Annals of surgery 206(3):358-365, 1987 [3]). Clearly, there is a need to improve the management of this disease. To identify gaps in research and formulate strategies to address these issues, we designed a framework to encompass the scope of research for pancreatic cancer. In this chapter, we will examine each topic heading within this framework for gaps in knowledge and present research strategies focusing on diverse comparative effectiveness research (CER) methodologies to address the identified gaps.
    Cancer treatment and research 02/2015; 164:165-194. DOI:10.1007/978-3-319-12553-4_10
  • [Show abstract] [Hide abstract]
    ABSTRACT: The worldwide incidence of melanoma continues to rise. It is a leading cause of cancer death and the second leading cause of loss of productive years of life. Although the diagnosis of melanoma is straightforward, there remain many controversies regarding treatment and surveillance. This chapter addresses important questions in melanoma treatment such as sentinel lymph node biopsy, what to do with a positive sentinel lymph node, margins of resection for melanoma, radiation for primary, nodal and metastatic melanoma, and routine use imaging. Through this chapter, the evidence for these controversial subjects and the barriers to resolution will be elucidated.
    Cancer treatment and research 02/2015; 164:31-49. DOI:10.1007/978-3-319-12553-4_3